Galantamine for treatment-resistant schizophrenia [3]

American Journal of Psychiatry

Volumn 159, Issue 7, 2002, Pages 1244-1245

  Allen, Trina B ^a   McEvoy, Joseph R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE;

AGITATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG BIOAVAILABILITY; LETTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT PLANNING;

ADULT; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; CLOZAPINE; DRUG THERAPY, COMBINATION; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; PARASYMPATHOMIMETICS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0036304121     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.7.1244     Document Type: Letter

References (6)

1. Schizophrenia, sensory gating, and nicotinic receptors
2. Gating of auditory P50 in schizophrenia: Unique effects of clozapine
3. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
4. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs were administered alone and together
5. Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors
6. Smoking and therapeutic response to clozapine in patients with schizophrenia